301201 Stock Overview
Engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
ChengDa Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥21.26 |
| 52 Week High | CN¥28.50 |
| 52 Week Low | CN¥14.60 |
| Beta | 0.30 |
| 11 Month Change | -0.56% |
| 3 Month Change | 21.21% |
| 1 Year Change | -24.61% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -27.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| 301201 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -7.2% | -1.5% | -2.1% |
| 1Y | -24.6% | -9.4% | 2.8% |
Return vs Industry: 301201 underperformed the CN Pharmaceuticals industry which returned -4.8% over the past year.
Return vs Market: 301201 underperformed the CN Market which returned 5.4% over the past year.
Price Volatility
| 301201 volatility | |
|---|---|
| 301201 Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 301201 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 301201's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 557 | Gang Lu | www.chengdapharm.com |
ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally. It offers APIs; bulk drugs for urogenital, musculoskeletal system, and antineoplastic and immunomodulators; and drug intermediates for blood and hematopoietic organs, digestive tract and metabolism, and nervous system. The company was founded in 1980 and is based in Jiaxing, China.
ChengDa Pharmaceuticals Co., Ltd. Fundamentals Summary
| 301201 fundamental statistics | |
|---|---|
| Market cap | CN¥3.22b |
| Earnings (TTM) | CN¥70.19m |
| Revenue (TTM) | CN¥397.81m |
45.9x
P/E Ratio8.1x
P/S RatioIs 301201 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301201 income statement (TTM) | |
|---|---|
| Revenue | CN¥397.81m |
| Cost of Revenue | CN¥223.85m |
| Gross Profit | CN¥173.96m |
| Other Expenses | CN¥103.77m |
| Earnings | CN¥70.19m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.46 |
| Gross Margin | 43.73% |
| Net Profit Margin | 17.64% |
| Debt/Equity Ratio | 0% |
How did 301201 perform over the long term?
See historical performance and comparison